Hpv 2025. Gavi, the vaccine alliance and partners have committed to reach 86 million adolescent girls with the human papillomavirus (hpv) vaccine by 2025, outlining an action plan following the gavi board’s approval of the revitalisation of the hpv programme. The vaccine protects against strains of the virus responsible for the majority of cervical cancers, as well as some cancers of the anus, vagina, and throat.
Get ready to be inspired, empowered, and enlightened at the asccp 2025 scientific meeting. Gavi, the vaccine alliance and partners have committed to reach 86 million adolescent girls with the human papillomavirus (hpv) vaccine by 2025, outlining an action plan following the gavi board’s approval of the revitalisation of the hpv programme.